Mesoblast Limited (NASDAQ:MESO) Receives Average Rating of "Buy" from Brokerages

Key Points

• Mesoblast Limited (NASDAQ:MESO) has received a consensus rating of "Buy" from five brokerages, with an average 1-year price objective of $18.00.
• Recent stock activity saw Mesoblast shares trading down 13.3% to $13.83, with a range between a 12-month low of $6.00 and a high of $22.00.
• Hedge funds have increased their investments in Mesoblast, with notable stakes acquired by Barclays PLC, JPMorgan Chase & Co., and BNP Paribas Financial Markets.

Mesoblast Limited (NASDAQ:MESO - Get Free Report) has earned a consensus rating of "Buy" from the five analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, two have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $18.00.

Several brokerages recently commented on MESO. Jefferies Financial Group cut shares of Mesoblast from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Canaccord Genuity Group upgraded shares of Mesoblast to a "strong-buy" rating in a research report on Tuesday, August 5th.

Hedge Funds Weigh In On Mesoblast

A number of hedge funds and other institutional investors have recently made changes to their positions in MESO. Barclays PLC bought a new position in shares of Mesoblast in the fourth quarter worth approximately $38,000. JPMorgan Chase & Co. purchased a new position in shares of Mesoblast during the 4th quarter valued at about $50,000. BNP Paribas Financial Markets lifted its holdings in Mesoblast by 86,566.7% in the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after purchasing an additional 2,597 shares in the last quarter. Tower Research Capital LLC TRC bought a new position in shares of Mesoblast during the 4th quarter valued at approximately $88,000. Finally, Advisors Preferred LLC grew its position in Mesoblast by 224.9% in the 1st quarter. Advisors Preferred LLC now owns 4,578 shares of the company's stock valued at $54,000 after acquiring an additional 3,169 shares during the last quarter. 1.43% of the stock is owned by hedge funds and other institutional investors.

Mesoblast Price Performance

Mesoblast stock traded down $0.24 during midday trading on Tuesday, hitting $12.88. 362,661 shares of the stock were exchanged, compared to its average volume of 146,473. Mesoblast has a 52 week low of $6.00 and a 52 week high of $22.00. The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 0.22. The company has a fifty day simple moving average of $13.95 and a two-hundred day simple moving average of $12.88.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.